Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) CEO Corey N. Fishman purchased 10,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was bought at an average cost of $1.59 per share, with a total value of $15,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 54,449 shares of the company’s stock, valued at approximately $86,573.91. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Iterum Therapeutics Stock Performance
Shares of NASDAQ:ITRM traded down $0.23 during trading on Monday, hitting $1.38. 369,337 shares of the stock traded hands, compared to its average volume of 65,357. The company has a fifty day moving average price of $0.76 and a two-hundred day moving average price of $0.96. Iterum Therapeutics plc has a 52-week low of $0.60 and a 52-week high of $1.80. The company has a market cap of $18.01 million, a price-to-earnings ratio of -0.59 and a beta of 1.63. The company has a quick ratio of 4.40, a current ratio of 2.35 and a debt-to-equity ratio of 3.63.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in shares of Iterum Therapeutics during the 2nd quarter valued at about $61,000. Renaissance Technologies LLC grew its holdings in Iterum Therapeutics by 199.1% in the second quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock valued at $65,000 after purchasing an additional 215,200 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Iterum Therapeutics in the third quarter valued at approximately $101,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Iterum Therapeutics during the 2nd quarter worth approximately $214,000. Hedge funds and other institutional investors own 3.39% of the company’s stock.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
- Five stocks we like better than Iterum Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The most upgraded stocks in November have two things in common
- What Are Dividend Achievers? An Introduction
- Monday.com rocked earnings like it’s the weekend
- Why Invest in High-Yield Dividend Stocks?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.